½ÃÀ庸°í¼­
»óǰÄÚµå
1448760

¼¼°èÀÇ ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Real-time PCR, Digital PCR, And End-point PCR Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 292 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ¼ö¿ä´Â 2023³â 81¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2032³â¿¡´Â ¾à 128¾ï 1,000¸¸ ´Þ·¯ ½ÃÀå ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ 2024³âºÎÅÍ 2032³â±îÁö CAGRÀº 5.14%·Î Àü¸ÁµË´Ï´Ù.

ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR)Àº DNAÀÇ ÁõÆø°ú ºÐ¼®¿¡ »ç¿ëµÇ´Â ºÐÀÚ »ý¹°ÇÐ ±â¼úÀÔ´Ï´Ù. PCR¿¡´Â ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR µî ¿©·¯ °¡Áö º¯ÇüÀÌ ÀÖÀ¸¸ç, °¢°¢ ¿ëµµ¿Í ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

PCR ±â¼ú¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä´Â COVID-19 °Ë»ç¿¡¼­ÀÇ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒ ¶§¹®¿¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ÆÒµ¥¹ÍÀº SARS-CoV-2 ¹ÙÀÌ·¯½ºÀÇ À¯Àü ¹°ÁúÀÇ °ËÃâ¿¡ À־ ±× Á߿伺À» ºÎ°¢½ÃÄ×½À´Ï´Ù. °¨¿°Áõ Áø´Ü¿¡ ±¹ÇѵÇÁö ¾Ê°í PCRÀº ºÐÀÚÁø´ÜÀÇ ÇÙ½ÉÀÌ¸ç ±× È®Àå¿¡ ±â¿©ÇÕ´Ï´Ù. »ý¸í°úÇÐ ¿¬±¸, ƯÈ÷ À¯ÀüüÇÐ¿Í ´Ü¹éÁúüÇÐÀÇ Áøº¸°¡ ÀÌ ±â¼ú ¼ö¿ä¸¦ ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. À¯Àü ÁúȯÀÇ Áõ·Ê Áõ°¡ ¹× Á¤È®ÇÑ Á¶±â Áø´ÜÀÇ Çʿ伺Àº À¯Àü °Ë»ç¿¡¼­ PCR ±â¹Ý Á¢±Ù¹ýÀÇ Ã¤ÅÃÀ» µÞ¹ÞħÇÕ´Ï´Ù. ½Ç½Ã°£ PCR°ú µðÁöÅÐ PCRÀ» Æ÷ÇÔÇÑ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀº DNA ÁõÆøÀÇ È¿À²¼º°ú °¨µµ¸¦ ³ôÀÌ°í ½ÃÀå ¼ºÀåÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç ¼Ö·ç¼Ç ¼ö¿ä ¹× ½Å¼Ó Áø´Ü¿¡ ÈÞ´ë¿ë PCR ±â¼úÀÇ ÀÀ¿ëÀÌ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷¿¡¼­ PCRÀº ÀǾàǰ °³¹ß, ¹ß°ß, ǰÁú °ü¸®¿¡ ÇʼöÀûÀÌ¸ç ½ÃÀåÀÇ Á¸Àç°¨À» ´õ¿í ³ô¿©ÁÖ°í ÀÖ½À´Ï´Ù. PCRÀÌ °è¼Ó ÁøÈ­ÇÏ°í ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ÀÀ¿ëµÊ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀº Áö¼ÓµÇ°í Áø´Ü ¹× ¿¬±¸ ¿ä±¸ÀÇ º¯È­¿¡ ÀûÀÀÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Â ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í °æÀïÀÇ ¸Å·ÂÀ» ¼¼°è ¼öÁØ¿¡¼­ Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ¼¼°èÀÇ ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR »ê¾÷ÀÇ ¼ºÀå ¹× µ¿ÇâÀº º» ¿¬±¸¿¡ Àü¹ÝÀûÀÎ Á¢±Ù¹ýÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇϹǷΠÀü·« ´ã´çÀÚ°¡ ÇâÈÄ ºñÁî´Ï½º ±âȸ¿Í °¢ Á¦Ç° ¶Ç´Â ¼­ºñ½ºÀÇ ´ë»ó °èÃþÀ» È®ÀÎÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

±â¼úº°

  • Á¤·®
  • µðÁöÅÐ
  • ¿£µåÆ÷ÀÎÆ®

Á¦Ç°º°

  • ¼Ò¸ðǰ ¹× ½Ã¾à
  • ±â±â
  • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

¿ëµµ À¯Çüº°

  • ÀÓ»ó(º´¿øÃ¼ °Ë»ç, Á¾¾ç °Ë»ç, Ç÷¾× ½ºÅ©¸®´×, ¾×ü »ý°Ë, dPCR ±â¹Ý ºñħ½ÀÀû Ãâ»ý Àü °Ë»ç(NIPT), ±âŸ)
  • ¿¬±¸(Áٱ⼼Æ÷ ¿¬±¸, DNA Ŭ·Î´× ¹× ½ÃÄö½Ì, ÀçÁ¶ÇÕ DNA ±â¼ú, Èñ¼Ò º¯ÀÌ °ËÃâ, À¯ÀüÀÚ ¹ßÇö, ½Ì±Û¼¿ ÇØ¼®, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ÇØ¼®, Ä«ÇǼö º¯µ¿ ÇØ¼®, ¶óÀ̺귯¸® Á¤·®(NGS), mRNA¿Í miRNAÀÇ ÀúÆúµå º¯È­ÀÇ Æ¯¼º ºÐ¼®, À¯ÀüÀÚ º¯Çü °ËÃâ)
  • ¹ýÀÇÇÐ

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡¼­ ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ª¿¡¼­ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÁßÁ¡À» µÓ´Ï´Ù.

¸ÂÃ㠿䱸»çÇ×ÀÌ ÀÖÀ¸¸é, ÀúÈñ¿¡°Ô ¿¬¶ôÇØ ÁÖ¼¼¿ä. ´ç»çÀÇ ¼³¹®Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR-»ê¾÷ ºÐ¼®

  • ¼­¹® : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ±¸¸ÅÀÚ ¸ñ·Ï
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼® : ±â¼úº°

  • ±â¼úº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ±â¼úº° ºÐ¼®
  • Á¤·®
  • µðÁöÅÐ
  • ¿£µåÆ÷ÀÎÆ®

Á¦6Àå ¼¼°èÀÇ ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • Á¦Ç°º° ºÐ¼®
  • ¼Ò¸ðǰ ¹× ½Ã¾à
  • ±â±â
  • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

Á¦7Àå ¼¼°èÀÇ ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼® : ¿ëµµ À¯Çüº°

  • ¿ëµµ À¯Çüº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ¿ëµµ À¯Çüº° ºÐ¼®
  • ÀÓ»ó(º´¿øÃ¼ °Ë»ç, Á¾¾ç °Ë»ç, Ç÷¾× ½ºÅ©¸®´×, ¾×ü »ý°Ë, dPCR ±â¹Ý ºñħ½ÀÀû Ãâ»ý Àü °Ë»ç(NIPT), ±âŸ)
  • ¿¬±¸(Áٱ⼼Æ÷ ¿¬±¸, DNA Ŭ·Î´× ¹× ½ÃÄö½Ì, ÀçÁ¶ÇÕ DNA ±â¼ú, Èñ¼Ò º¯ÀÌ °ËÃâ, À¯ÀüÀÚ ¹ßÇö, ½Ì±Û¼¿ ÇØ¼®, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ÇØ¼®, Ä«ÇǼö º¯µ¿ ÇØ¼®, ¶óÀ̺귯¸® Á¤·®(NGS), mRNA¿Í miRNAÀÇ ÀúÆúµå º¯È­ÀÇ Æ¯¼º ºÐ¼®, À¯ÀüÀÚ º¯Çü °ËÃâ)
  • ¹ýÀÇÇÐ

Á¦8Àå ¼¼°èÀÇ ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­¹®
  • ºÏ¹ÌÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ±â¾÷ °æÀï ±¸µµ

  • ½Ç½Ã°£ PCR, µðÁöÅÐ PCR ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå °æÀï
  • ÆÄÆ®³Ê½Ê, Á¦ÈÞ ¹× ÇÕÀÇ
  • ÇÕº´ ¹× Àμö
  • ½ÅÁ¦Ç° ¹ßÇ¥
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Abbott
  • Qiagen
  • Bio-Rad Laboratories Inc.
  • Agilent Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • GE Healthcare
  • bioMerieux
  • F. Hoffmann-La Roche Ltd
  • Fluidigm Corporation
AJY 24.03.28

The global demand for Real-time PCR, Digital PCR, And End-point PCR Market is presumed to reach the market size of nearly USD 12.81 BN by 2032 from USD 8.16 BN in 2023 with a CAGR of 5.14% under the study period 2024 - 2032.

Polymerase Chain Reaction (PCR) is a molecular biology technique used to amplify and analyze DNA. There are several variations of PCR, including real-time PCR, digital PCR, and endpoint PCR, each with its own applications and advantages.

MARKET DYNAMICS

The global demand for PCR technology has surged due to its pivotal role in COVID-19 testing. The pandemic has highlighted its importance in detecting the genetic material of the SARS-CoV-2 virus. Beyond infectious disease diagnostics, PCR remains a cornerstone in molecular diagnostics, contributing to its expansion. Advances in life sciences research, particularly in genomics and proteomics, further fuel the demand for this technology. The rising cases of genetic disorders and the need for precise and early diagnosis propel the adoption of PCR-based methods in genetic testing. Continuous technological advancements, including real-time PCR and digital PCR, enhance the efficiency and sensitivity of DNA amplification, reinforcing market growth. Additionally, the demand for point-of-care testing solutions and the application of portable PCR technologies in rapid diagnostics contribute to the market's expansion. In the pharmaceutical and biotechnology industries, PCR is integral for drug development, discovery, and quality control, further driving its market presence. As PCR continues to evolve and find applications across diverse sectors, its market growth is expected to persist, adapting to the changing landscape of diagnostic and research needs.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of real-time pcr, digital pcr, and end-point pcr. The growth and trends of real-time pcr, digital pcr, and end-point pcr industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the real-time pcr, digital pcr, and end-point pcr market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

  • Quantitative
  • Digital
  • End-Point

By Product

  • Consumables & Reagents
  • Instruments
  • Software & Services

By Application Type

  • Clinical (Pathogen Testing, Oncology Testing, Blood Screening, Liquid Biopsy, Dpcr-Based Non-Invasive Prenatal Testing (Nipt), Others)
  • Research (Stem Cell Research, DNA Cloning & Sequencing, Recombinant DNA Technology, Rare Mutation Detection, Gene Expression, Single Cell Analysis, Microbiome Analysis, Copy Number Variation Analysis, Library Quantification (NGS), Characterization of Low-fold Changes in mRNA and miRNA, GMO Detection)
  • Forensic

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Real-time PCR, Digital PCR, And End-point PCR market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Real-time PCR, Digital PCR, And End-point PCR market include Abbott, Qiagen, Bio-Rad Laboratories Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., GE Healthcare, bioMerieux, F. Hoffmann-La Roche Ltd, Fluidigm Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . REAL-TIME PCR, DIGITAL PCR, AND END-POINT PCR - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Technology
    • 3.7.2 Market Attractiveness Analysis By Product
    • 3.7.3 Market Attractiveness Analysis By Application Type
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL REAL-TIME PCR, DIGITAL PCR, AND END-POINT PCR MARKET ANALYSIS BY TECHNOLOGY

  • 5.1 Overview by Technology
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Technology
  • 5.4 Quantitative Historic and Forecast Sales by Regions
  • 5.5 Digital Historic and Forecast Sales by Regions
  • 5.6 End-point Historic and Forecast Sales by Regions

6 . GLOBAL REAL-TIME PCR, DIGITAL PCR, AND END-POINT PCR MARKET ANALYSIS BY PRODUCT

  • 6.1 Overview by Product
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Product
  • 6.4 Consumables & Reagents Historic and Forecast Sales by Regions
  • 6.5 Instruments Historic and Forecast Sales by Regions
  • 6.6 Software & Services Historic and Forecast Sales by Regions

7 . GLOBAL REAL-TIME PCR, DIGITAL PCR, AND END-POINT PCR MARKET ANALYSIS BY APPLICATION TYPE

  • 7.1 Overview by Application Type
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Application Type
  • 7.4 Clinical (Pathogen Testing, Oncology Testing, Blood Screening, Liquid Biopsy, dPCR-based Non-Invasive Prenatal Testing (NIPT), Others) Historic and Forecast Sales by Regions
  • 7.5 Research (Stem Cell Research, DNA Cloning & Sequencing, Recombinant DNA Technology, Rare Mutation Detection, Gene Expression, Single Cell Analysis, Microbiome Analysis, Copy Number Variation Analysis, Library Quantification (NGS), Characterization of Low-fold Changes in mRNA and miRNA, GMO Detection) Historic and Forecast Sales by Regions
  • 7.6 Forensic Historic and Forecast Sales by Regions

8 . GLOBAL REAL-TIME PCR, DIGITAL PCR, AND END-POINT PCR MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE REAL-TIME PCR, DIGITAL PCR, AND END-POINT PCR COMPANIES

  • 9.1. Real-Time Pcr, Digital Pcr, And End-Point Pcr Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF REAL-TIME PCR, DIGITAL PCR, AND END-POINT PCR INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Abbott
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Qiagen
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Bio-Rad Laboratories Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Agilent Technologies Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Thermo Fisher Scientific Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. GE Healthcare
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. bioMerieux
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. F. Hoffmann-La Roche Ltd
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Fluidigm Corporation
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦